Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Int J Mol Med ; 22(3): 317-23, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18698490

ABSTRACT

Glucosamine, a naturally occurring amino monosaccharide, is widely used to treat osteoarthritis in humans. Furthermore, glucosamine exhibits an anti-inflammatory action by inhibiting the activation of neutrophils, chondrocytes and synoviocytes. Recently, we revealed that glucosamine suppresses cytokine-induced activation of intestinal epithelial cells in vitro. In the present study therefore, we investigated whether glucosamine exhibits the anti-inflammatory effect in vivo, using dextran sulfate sodium (DSS)-induced colitis in rats, a model of inflammatory bowel diseases (IBD). The results indicated that glucosamine improved the clinical symptoms (evaluated by disease activity index), and suppressed colonic inflammation (evaluated by colon length and weight/length ratio) and tissue injury (evaluated by histological damage score) in DSS-induced colitis. Furthermore, glucosamine inhibited the activation of intestinal epithelial cells, as evidenced by the suppressed phosphorylation of NF-kappaB in the intestinal mucosa of DSS-induced colitis. Collectively, these observations suggest that glucosamine is likely to suppress the activation of intestinal epithelial cells in vivo, thereby possibly exhibiting anti-inflammatory action in a DSS-induced rat colitis model. Thus, glucosamine could prove to be a useful agent for IBD.


Subject(s)
Biological Products/therapeutic use , Colitis/drug therapy , Colitis/pathology , Dextran Sulfate/pharmacology , Glucosamine/therapeutic use , Monosaccharides/therapeutic use , Animals , CD11b Antigen/metabolism , Colitis/chemically induced , Colitis/metabolism , Cytokines/metabolism , Male , NF-kappa B/metabolism , Neutrophils/drug effects , Neutrophils/metabolism , Phosphorylation , Rats , Rats, Sprague-Dawley
2.
Int Immunol ; 20(4): 543-53, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18308714

ABSTRACT

Peptide antibiotics possess the potent antimicrobial activities against invading microorganisms and contribute to the innate host defense. Antimicrobial human beta-defensins (hBDs) not only exhibit potent bactericidal activities against Gram-negative and Gram-positive bacteria but also function as immunomodulatory molecules by inducing cytokine and chemokine production and inflammatory and immune cell activation. Neutrophil is a critical effector cell in host defense against microbial infection, and its lifespan is regulated by various pathogen- and host-derived substances. Here, to further evaluate the role of hBDs in innate immunity, we investigated the action of hBD-1 to -4 on neutrophil apoptosis. Neutrophil apoptosis was assessed using human blood neutrophils based on the morphological changes. Of note, hBD-3 most potently suppressed neutrophil apoptosis among hBD-1 to -4, accompanied with the down-regulation of truncated Bid (a pro-apoptotic protein), up-regulation of Bcl-x(L) (an anti-apoptotic protein) and inhibition of mitochondrial membrane potential change and caspase 3 activity. Furthermore, we revealed that neutrophils expressed CC chemokine receptor (CCR) 6, and the action of hBD-3 was completely abrogated by a neutralizing anti-CCR6 mAb. Collectively, these observations suggest that hBDs, especially hBD-3, can not only kill bacteria but also modulate (suppress) neutrophil apoptosis via the action on CCR6. Suppression of neutrophil apoptosis results in the prolongation of their lifespan and may be advantageous for the host defense against bacterial invasion.


Subject(s)
Apoptosis/drug effects , Neutrophils/drug effects , beta-Defensins/pharmacology , Antibodies, Monoclonal/metabolism , Antigen-Antibody Reactions , Apoptosis/immunology , BH3 Interacting Domain Death Agonist Protein/biosynthesis , BH3 Interacting Domain Death Agonist Protein/drug effects , BH3 Interacting Domain Death Agonist Protein/immunology , Calcium/metabolism , Caspase 3/drug effects , Caspase 3/metabolism , Cytokines/biosynthesis , Cytokines/drug effects , Enzyme Activation/drug effects , Enzyme Activation/immunology , Humans , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Mitochondrial Membranes/drug effects , Mitochondrial Membranes/metabolism , Neutrophils/cytology , Neutrophils/immunology , Receptors, CCR6/metabolism , bcl-X Protein/biosynthesis , bcl-X Protein/drug effects , bcl-X Protein/immunology
3.
Int Immunol ; 20(2): 199-208, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18056918

ABSTRACT

Chlamydiaceae are small obligate intracellular parasites and classified as Gram-negative bacteria. Among Chlamydiaceae-derived components, LPS is known as an immunomodulator and possesses a unique lipid A structure with longer but fewer acyl chains. In this study, to elucidate the Chlamydiaceae-induced immune responses, we evaluated the actions of Chlamydophila psittaci LPS as a Chlamydiaceae LPS on human PBMCs and compared with those of Escherichia coli LPS. Similar to E. coli LPS, C. psittaci LPS bound to monocytes and induced the pro-inflammatory cytokine production in an LPS-binding protein (LBP)-dependent manner. However, C. psittaci LPS was much less potent than E. coli LPS in both the LPS binding and cytokine production. Interestingly, although the binding of C. psittaci LPS was mediated by CD14, Toll-like receptor 4 (TLR4) and CD11b, CD14 and TLR4 but not CD11b were involved in the cytokine production. Of note, ELISA-based binding assays revealed that C. psittaci LPS directly bound to LBP and CD14; however, the affinities were much less than those of E. coli LPS. Together, these observations possibly suggest that Chlamydiaceae LPS has low binding affinities for LPS recognition molecules such as CD14 and LBP and exhibit weak biological activities against host immune cells including monocytes, thereby contributing to the chronic (persistent) inflammatory reactions during infection.


Subject(s)
Acute-Phase Proteins/metabolism , Carrier Proteins/metabolism , Chlamydiaceae/immunology , Leukocytes, Mononuclear/immunology , Lipopolysaccharide Receptors/metabolism , Lipopolysaccharides/immunology , Lymphocyte Activation/immunology , Membrane Glycoproteins/metabolism , Chlamydophila psittaci/immunology , Cytokines/biosynthesis , Escherichia coli/immunology , Humans , Leukocytes, Mononuclear/drug effects , Lipopolysaccharides/metabolism , Lipopolysaccharides/pharmacology , Lymphocyte Activation/drug effects , Toll-Like Receptor 4/metabolism
4.
Cancer Biol Ther ; 6(12): 1967-77, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18075297

ABSTRACT

Acute promyelocytic leukemia (APL) is associated with oncogenic PML-RARalpha that acts as a dominant negative transcriptional repressor of retinoic acid (RA) receptor target genes by recruiting histone deacetylase (HDAC). The peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the nuclear receptor family that forms heterodimers with retinoid X receptor (RXR). In addition to RAR targets, PML-RARalpha silence a wide range of nuclear receptor target genes including PPARgamma targets. All-trans-retinoic acid (ATRA), a ligand for the RA receptor (RAR), restores normal retinoid signaling and induces terminal differentiation of APL cells; however, APL cells can develop resistance to ATRA. Using ATRA sensitive NB4 and ATRA-resistant derivative MR2 cell lines, we demonstrate that PPARgamma ligand 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO) enhances pro-apoptotic and differentiating effects of ATRA in ATRA-sensitive NB4 cells and partially reverses ATRA resistance in MR2 cells. The CDDO/ATRA combination synergistically induces RARbeta2 expression both in ATRA-sensitive and -resistant APL cells. RARbeta2 MrNA induction by CDDO/ATRA was mediated in part by enhanced H3-Lys9 acetylation in the RARbeta2 promoter which in turn increased the affinity of RARbeta for betaRARE. PPARgamma specific inhibitor T007 and silencing of PPARgamma by siRNA diminished CDDO-induced maturation and RARbeta2 mRNA along with PPARgamma induction indicating that PPARgamma activation is at least partially responsible for the RARbeta2 transcription and maturation induction. In an in vivo mouse model of APL, CDDO derivative CDDO-methyl ester markedly enhanced ATRA-induced maturation and extended the survival of mice. In summary, these results provide rationale for the combined targeting of RAR and PPARgamma nuclear receptors in the therapy of APL.


Subject(s)
Antineoplastic Agents/pharmacology , Leukemia, Promyelocytic, Acute/drug therapy , Oleanolic Acid/analogs & derivatives , PPAR gamma/drug effects , Tretinoin/pharmacology , Acetylation/drug effects , Animals , Antineoplastic Agents/therapeutic use , Apoptosis/drug effects , Cell Differentiation/drug effects , Cell Line, Tumor/drug effects , Drug Resistance, Neoplasm/drug effects , Drug Screening Assays, Antitumor , Histones/metabolism , Humans , Mice , Mice, Transgenic , Nicotinic Acids/pharmacology , Oleanolic Acid/pharmacology , Oleanolic Acid/therapeutic use , Promoter Regions, Genetic/drug effects , Protein Processing, Post-Translational/drug effects , RNA, Small Interfering/pharmacology , Receptors, Retinoic Acid/genetics , Response Elements/drug effects , Tetrahydronaphthalenes/pharmacology , Tretinoin/agonists
5.
Cancer Res ; 67(2): 684-94, 2007 Jan 15.
Article in English | MEDLINE | ID: mdl-17234779

ABSTRACT

Integrin-linked kinase (ILK) directly interacts with beta integrins and phosphorylates Akt in a phosphatidylinositol 3-kinase (PI3K)-dependent manner. In this study, we examined the functional role of ILK activation in leukemic and bone marrow stromal cells on their direct contact. Coculture of leukemic NB4 cells with bone marrow-derived stromal mesenchymal stem cells (MSC) resulted in robust activation of multiple signaling pathways, including ILK/Akt, extracellular signal-regulated kinase 1/2 (ERK1/2), signal transducers and activators of transcription 3 (STAT3), and Notch1/Hes. Blockade of PI3K or ILK signaling with pharmacologic inhibitors LY294002 or QLT0267 specifically inhibited stroma-induced phosphorylation of Akt and glycogen synthase kinase 3beta, suppressed STAT3 and ERK1/2 activation, and decreased Notch1 and Hes1 expression in leukemic cells. This resulted in induction of apoptosis in both leukemic cell lines and in primary acute myelogenous leukemia samples that was not abrogated by MSC coculture. In turn, leukemic cells growing in direct contact with bone marrow stromal elements induce activation of Akt, ERK1/2, and STAT3 signaling in MSC, accompanied by significant increase in Hes1 and Bcl-2 proteins, which were all suppressed by QLT0267 and LY294002. In summary, our results indicate reciprocal activation of ILK/Akt in both leukemic and bone marrow stromal cells. We propose that ILK/Akt is a proximal signaling pathway critical for survival of leukemic cells within the bone marrow microenvironment. Hence, disruption of these interactions by ILK inhibitors represents a potential novel therapeutic strategy to eradicate leukemia in the bone marrow microenvironment by simultaneous targeting of both leukemic cells and activated bone marrow stromal cells.


Subject(s)
Cell Communication/physiology , Leukemia, Promyelocytic, Acute/enzymology , Mesenchymal Stem Cells/enzymology , Protein Serine-Threonine Kinases/metabolism , Basic Helix-Loop-Helix Transcription Factors/metabolism , Bone Marrow Cells/cytology , Bone Marrow Cells/enzymology , Cell Survival/physiology , Chromones/pharmacology , Coculture Techniques , Enzyme Activation/drug effects , Homeodomain Proteins/metabolism , Humans , Janus Kinases/metabolism , Leukemia, Promyelocytic, Acute/genetics , Leukemia, Promyelocytic, Acute/pathology , Mesenchymal Stem Cells/cytology , Mitogen-Activated Protein Kinase Kinases/metabolism , Morpholines/pharmacology , Phosphatidylinositol 3-Kinases/metabolism , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation/drug effects , Protein Serine-Threonine Kinases/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/metabolism , Receptors, Notch/metabolism , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Stromal Cells/cytology , Stromal Cells/enzymology , Transcription Factor HES-1
6.
Ann Hematol ; 85(10): 689-704, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16832676

ABSTRACT

The acute promyelocytic leukemia-specific PML-RARalpha fusion protein is a dominant-negative transcriptional repressor of retinoic acid receptor (RAR) target genes, which recruits HDAC and corepressor proteins and inhibits coactivators. Another oncogenic transcription factor, AML1-ETO, was proposed to cause an HDAC-dependent repression of RAR target genes. The RAR target RARbeta2 gene has been reported to be frequently silenced by hypermethylation in many types of cancer cells. We examined the methylation status of the RARbeta2 and asked if demethylation could reverse ATRA resistance in ATRA-resistant PML-RARalpha and AML1-ETO-positive cells. PML-RARalpha positive NB4 and its ATRA-resistant subvariant MR2 and AML1-ETO expressing Kasumi-1 cells had heterozygous methylation of RARbeta2. Although DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine partially reversed RARbeta2 CpG methylation in these cells, it did not significantly enhance ATRA-induced RARbeta2 mRNA expression and induction of maturation. However, the histone acetylase inhibitor SAHA combined with ATRA significantly reactivated RARbeta2 mRNA both in NB4 and MR2 cells with degradation of PML-RARalpha, which was associated with maturation. In contrast, SAHA did not affect AML1-ETO levels and failed to induce RARbeta2 expression and maturation in Kasumi-1 cells. In primary AML samples, RARbeta2 expression was uniformly low; however, no specific correlation was observed between the methylation of the RARbeta2 gene and expression of the fusion proteins, PML-RARalpha, and AML1-ETO. These results demonstrate that oncogenic PML-RARalpha and AML1-ETO translocations are rarely associated with RARbeta2 promoter methylation in primary AML samples.


Subject(s)
Core Binding Factor Alpha 2 Subunit/biosynthesis , DNA Methylation , Leukemia, Promyelocytic, Acute/metabolism , Oncogene Proteins, Fusion/biosynthesis , Promoter Regions, Genetic , Receptors, Retinoic Acid/biosynthesis , Translocation, Genetic , Antineoplastic Agents/pharmacology , Azacitidine/analogs & derivatives , Azacitidine/pharmacology , Core Binding Factor Alpha 2 Subunit/genetics , DNA (Cytosine-5-)-Methyltransferases/antagonists & inhibitors , DNA (Cytosine-5-)-Methyltransferases/metabolism , DNA Methylation/drug effects , Decitabine , Drug Resistance, Neoplasm/drug effects , Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Leukemic/drug effects , HL-60 Cells , Histone Deacetylases/biosynthesis , Histone Deacetylases/genetics , Humans , K562 Cells , Leukemia, Promyelocytic, Acute/genetics , Oncogene Proteins, Fusion/genetics , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , RNA, Neoplasm/biosynthesis , RNA, Neoplasm/genetics , RUNX1 Translocation Partner 1 Protein , Receptors, Retinoic Acid/genetics , Translocation, Genetic/drug effects , Translocation, Genetic/genetics , Tretinoin/pharmacology , U937 Cells
7.
Blood ; 107(4): 1546-54, 2006 Feb 15.
Article in English | MEDLINE | ID: mdl-16223781

ABSTRACT

The multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp) is frequently implicated in cross-resistance of tumors to chemotherapeutic drugs. In contrast, acute promyelocytic leukemia (APL) cells do not express MDR1 and are highly sensitive to anthracyclines. The combination of ATRA and the novel histone deacetylase inhibitor (HDACI) depsipeptide (FK228) induced P-gp expression and prevented growth inhibition and apoptosis in NB4 APL cells subsequently exposed to doxorubicin (DOX). ATRA/FK228 treatment after exposure to DOX, however, enhanced apoptosis. Both agents, ATRA or FK228, induced MDR1 mRNA. This effect was significantly enhanced by ATRA/FK228 administered in combination, due in part to increased H4 and H3-Lys9 acetylation of the MDR1 promoter and recruitment of the nuclear transcription factor Y alpha (NFYA) transcription activator to the CCAAT box. Cotreatment with specific P-gp inhibitor PSC833 reversed cytoprotective effects of ATRA/FK228. G1 cell-cycle arrest and p21 mRNA induction were also observed in response to ATRA/FK228, which may restrict DOX-induced apoptosis of cells in G2 phase. These results indicate that epigenetic mechanisms involving NF-YA transcription factor recruitment and histone acetylation are activated by ATRA and HDACI, induce MDR1 in APL cells, and point to the critical importance of mechanism-based sequential therapy in future clinical trials that combine HDAC inhibitors, ATRA, and anthracyclines.


Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics , Antibiotics, Antineoplastic/pharmacology , Depsipeptides/pharmacology , Doxorubicin/pharmacology , Drug Resistance, Neoplasm/physiology , Leukemia, Promyelocytic, Acute/genetics , Cell Cycle/drug effects , Enzyme Inhibitors/pharmacology , Genes, MDR , Histone Deacetylase Inhibitors , Humans
8.
Pathol Int ; 54(1): 41-6, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14674994

ABSTRACT

Two Japanese brothers were diagnosed in their 20s with familial pulmonary fibrosis, the pathological findings of which were consistent with usual interstitial pneumonia (UIP). However, an atypical characteristic was observed in the lungs of these brothers; 2-mm areas of 'honeycomb' were identified throughout the lungs, which is smaller than the generally observed 5-10 mm honeycombing seen in UIP. Fibroblastic foci were demonstrated in the second eldest brother, but not in the eldest, which indicates that the lungs of the eldest brother was in a more advanced stage of fibrosis. Their youngest brother and parents have no clinical evidence of pulmonary fibrosis. All five family members had low values for the diffusion capacity of the lung for carbon monoxide (DLCO), suggesting the presence of an inheritable disease and the existence of different phenotypes. The genomic DNA of the affected brothers was sequenced for the reported surfactant protein C (SP-C) gene mutations in patients with familial pulmonary fibrosis, but none was documented. It is necessary to clarify the presence of novel gene mutations of SP-C or other genes to explain these particular pathological findings and the low DLCO observed in this family.


Subject(s)
Genetic Predisposition to Disease , Lung Diseases, Interstitial/genetics , Lung Diseases, Interstitial/pathology , Pulmonary Fibrosis/genetics , Pulmonary Fibrosis/pathology , Adult , Carbon Monoxide/metabolism , Consanguinity , DNA Mutational Analysis , Fatal Outcome , Female , Humans , Lung Diseases, Interstitial/metabolism , Male , Pedigree , Pulmonary Diffusing Capacity , Pulmonary Fibrosis/metabolism , Pulmonary Surfactant-Associated Protein C/genetics , Pulmonary Surfactant-Associated Protein C/metabolism , Radiography, Thoracic , Siblings
9.
Exp Lung Res ; 29(6): 389-400, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12888451

ABSTRACT

Recruitment of neutrophils into the alveoli plays a major role in the pathogenesis of acid-induced pneumonitis. Preliminary data suggest that alteration in the expression of cellular adhesion molecules on the airway epithelial cells may play an important role in the recruitment of neutrophils following acid-induced lung injury. The aim of this study was to evaluate the change in the surface expression of intercellular adhesion molecule-1 (ICAM-1), E-cadherin, and vascular cell adhesion molecule -1 (VCAM-1) on acid-exposed A549 alveolar lining epithelial cells by flow cytometry and confocal laser microscopy. Acid exposure changed cell morphology, increased cell adhesion after trypsin-EDTA treatment, and up-regulated the expression of ICAM-1 and E-cadherin but not of VCAM-1. The up-regulation of ICAM-1 expression will induce the dysfunction of epithelial cells with or without accumulation of neutrophils in air spaces. Because the distribution of E-cadherin in acid-exposed A549 cells was at the sites where the cells attached to culture dish but not at the intercellular junctions between adjoining cells, up-regulated expression of E-cadherin will rather result in alterations of epithelial morphology and function of epithelial barrier. In addition, pentoxifylline suppressed the up-regulation of ICAM-1 and E-cadherin expression and may therefore attenuated the airway inflammation in acid-induced pneumonitis.


Subject(s)
Cadherins/metabolism , Epithelial Cells/drug effects , Hydrochloric Acid/pharmacology , Intercellular Adhesion Molecule-1/metabolism , Pulmonary Alveoli/drug effects , Cell Adhesion/drug effects , Cell Line, Tumor , Epithelial Cells/cytology , Epithelial Cells/metabolism , Flow Cytometry , Humans , Microscopy, Confocal , Pentoxifylline/pharmacology , Pulmonary Alveoli/cytology , Pulmonary Alveoli/metabolism , Vascular Cell Adhesion Molecule-1/metabolism
10.
J Immunol ; 170(8): 4226-36, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12682256

ABSTRACT

Human beta-defensin (hBD)-2, a cationic antimicrobial peptide primarily induced in epithelial cells in response to inflammatory stimuli, plays an important role in host defense. To elucidate the expression mechanism of hBD-2 in the lung, we investigated the modulation of hBD-2 transcription in pulmonary epithelial cells by mononuclear phagocytes stimulated with LPS. Coculture of A549 pulmonary epithelial cells with Mono-Mac-6 monocytic cells in the presence of Escherichia coli LPS markedly up-regulated hBD-2 promoter activity, whereas A549 alone did not respond to LPS to activate the hBD-2 promoter. Furthermore, IL-1beta and TNF-alpha in the culture supernatants from LPS-stimulated monocytic cells activated the hBD-2 promoter in A549 cells. Of note, IL-1beta was more potent than TNF-alpha in this effect. In addition, a mutation of the NF-kappaB site at -200 (pkappaB1 site) completely abolished this IL-1beta- and TNF-alpha-induced hBD-2 promoter activation, whereas NF-kappaB inhibitors (MG-132 and helenalin) strongly suppressed it. Moreover, electrophoretic mobility shift assay suggested that NF-kappaB, consisting of p65-p50 heterodimer, could bind to the pkappaB1 site in cytokine-stimulated A549 cells. Interestingly, flow cytometric analysis revealed that A549 cells expressed CD14 but lacked Toll-like receptor 4, which may account for the hyporesponsiveness of A549 cells to LPS. Taken together, these results suggest that hBD-2 expression in pulmonary epithelial cells is modulated by NF-kappaB via the actions of IL-1beta and TNF-alpha produced by LPS-stimulated mononuclear phagocytes.


Subject(s)
Cytokines/biosynthesis , Epithelial Cells/immunology , Gene Expression Regulation/immunology , Inflammation Mediators/pharmacology , Lipopolysaccharides/pharmacology , Monocytes/immunology , Pulmonary Alveoli/immunology , beta-Defensins/genetics , Cell Line , Cytokines/physiology , Enzyme Inhibitors/pharmacology , Epithelial Cells/metabolism , Humans , Interleukin-1/antagonists & inhibitors , Interleukin-1/biosynthesis , Interleukin-1/physiology , Lipopolysaccharide Receptors/biosynthesis , Lipopolysaccharides/metabolism , Membrane Glycoproteins/biosynthesis , Monocytes/metabolism , Multigene Family/immunology , NF-kappa B/antagonists & inhibitors , NF-kappa B/metabolism , Promoter Regions, Genetic/immunology , Pulmonary Alveoli/cytology , Pulmonary Alveoli/metabolism , Receptors, Cell Surface/biosynthesis , Response Elements/immunology , Toll-Like Receptor 4 , Toll-Like Receptors , Transcription, Genetic/immunology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/physiology , U937 Cells , beta-Defensins/antagonists & inhibitors , beta-Defensins/metabolism
11.
J Leukoc Biol ; 71(1): 154-62, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11781391

ABSTRACT

beta-Defensins are cationic peptides with broad-spectrum antimicrobial activities that contribute to innate host defense. Among human beta-defensins (hBDs), hBD-2 is up-regulated in epithelial tissues and mononuclear phagocytes in response to bacterial infection and proinflammatory cytokines. However, little is known about the molecular mechanism of hBD-2 gene regulation. Here, we investigated lipopolysaccharide (LPS)-mediated transcriptional regulation of the hBD-2 gene by focusing on the roles of NF-kappa B, STAT, and NF-IL-6 sites in mononuclear phagocytes using RAW264.7 cells, which are sensitive to LPS. Luciferase reporter analyses demonstrated that two NF-kappa B sites were essential for full LPS responsiveness of the hBD-2 gene. Further, both NF-kappa B sites were also crucial for basal transcriptional activity. In contrast, neither the NF-IL-6 nor STAT binding site was required for LPS-induced hBD-2 transcription. Electrophoretic mobility shift assay indicated that in unstimulated cells, NF-kappa B p50 homodimer bound to both NF-kappa B sites, whereas the p65-p50 heterodimer formed complexes with these sites following LPS stimulation. Together, these observations indicate that NF-kappa B plays an important role in the regulation of hBD-2 gene expression in response to LPS.


Subject(s)
Anti-Infective Agents , Lipopolysaccharides/pharmacology , Transcriptional Activation/drug effects , beta-Defensins/genetics , Animals , CCAAT-Enhancer-Binding Protein-beta/genetics , Cell Line , Humans , Mice , NF-kappa B/genetics , Trans-Activators/genetics , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...